Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Neurodegener Dis ; 17(1): 44-58, 2017.
Article in English | MEDLINE | ID: mdl-27617773

ABSTRACT

BACKGROUND: The survival of motor neurons is dependent upon neurotrophic factors both during childhood and adolescence and during adult life. In disease conditions, such as in patients with amyotrophic lateral sclerosis (ALS), the mRNA levels of trophic factors like brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1), fibroblast growth factor-2 (FGF-2), and vascular endothelial growth factor are downregulated. This was replicated in our in vivo experimental system following the injection of cerebral spinal fluid (CSF) of sporadic ALS (ALS-CSF) patients. OBJECTIVE: To evaluate the protective role of BDNF in a model of sporadic ALS patients. METHODS: The expressions of endogenous BDNF, its receptor TrkB, the enzyme choline acetyl transferase (ChAT), and phosphorylated neurofilaments were studied in NSC-34 cells. The calcium-buffering and proapoptotic effects were assessed by calbindin-D28K and caspase-3 expression, respectively. RESULTS: ALS-CSF considerably depleted the endogenous BDNF protein, while its effect on IGF-1 and FGF-2 was inconsequential; this indirectly indicates a key role for BDNF in supporting motor neuronal survival. The exogenous supplementation of BDNF reversed autocrine expression; however, it may not be completely receptor mediated, as the TrkB levels were not restored. BDNF completely revived ChAT expression. It may inhibit apoptosis by restoring Ca2+ homeostasis, since caspase-3 and calbindin-D28K expression was back to normal. The organellar ultrastructural changes were only partially reversed. CONCLUSION: Our study provides evidence that BDNF supplementation ameliorates most but not all degenerative changes. The incomplete revival at the ultrastructural level signifies the requirement of factors other than BDNF for near-total protection of motor neurons, and, to an extent, it explains why only a partial success is achieved in clinical trials with BDNF in ALS patients.


Subject(s)
Amyotrophic Lateral Sclerosis/cerebrospinal fluid , Brain-Derived Neurotrophic Factor/pharmacology , Motor Neurons/drug effects , Nerve Degeneration/drug therapy , Neuroprotective Agents/pharmacology , Recovery of Function/drug effects , Animals , Apoptosis/drug effects , Apoptosis/physiology , Brain-Derived Neurotrophic Factor/metabolism , Calcium/metabolism , Cell Line , Cell Survival/drug effects , Disease Models, Animal , Humans , Intermediate Filaments/drug effects , Intermediate Filaments/metabolism , Intermediate Filaments/pathology , Mice , Motor Neurons/physiology , Motor Neurons/ultrastructure , Nerve Degeneration/pathology , Nerve Degeneration/physiopathology , Rats, Wistar , Receptor, trkB/metabolism , Recovery of Function/physiology , Spinal Cord/drug effects , Spinal Cord/pathology , Spinal Cord/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...